Evercore ISI Begins Coverage on Akero Therapeutics (NASDAQ:AKRO)

Evercore ISI initiated coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a research note released on Monday, Briefing.com Automated Import reports. The firm issued an outperform rating and a $35.00 price target on the stock.

AKRO has been the topic of a number of other research reports. Jefferies Financial Group set a $189.00 price target on shares of salesforce.com and gave the stock a buy rating in a research note on Monday. JPMorgan Chase & Co. reiterated a sell rating and issued a $18.00 price target on shares of ABB in a research note on Monday. Finally, Roth Capital reiterated a buy rating on shares of Coeur Mining in a research note on Monday.

Shares of Akero Therapeutics stock opened at $20.64 on Monday. Akero Therapeutics has a 1 year low of $16.06 and a 1 year high of $21.94.



In related news, Director Seth Loring Harrison bought 900,000 shares of the stock in a transaction on Monday, June 24th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $14,400,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Global Strategic Fund I. Venbio bought 250,000 shares of the stock in a transaction on Monday, June 24th. The shares were bought at an average price of $16.00 per share, for a total transaction of $4,000,000.00. The disclosure for this purchase can be found here.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Featured Article: Are we seeing the beginning of a new bubble?

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.